Omar Noor, MD, FAAD, provides insights from a case-based discussion, wherein he navigates the complexities surrounding patient care, emphasizing the critical importance of patient education, trust-building, and equitable access to care. He also explores the nuanced implications of boxed warnings linked to JAK inhibitors, drawing attention to variations between systemic and oral forms of topical ruxolitinib, and their potential influence on dialogues with patients and fellow healthcare providers.
EP. 1: Case 1: Female, 28 Years Old, African American
November 8th 2023Omar Noor, MD, FAAD, discusses the critical role of patient education and transparent communication in the context of treating individuals with atopic dermatitis. He emphasizes the significance of cultivating trust in patient-provider relationships, explores the potential necessity of shifting the treatment paradigm, and addresses the implications of treatment interruptions or transitions in the long-term management of this condition, all while considering the crucial aspect of access to care.
EP. 2: Case 2: Male, 58 Years Old with AD
November 8th 2023Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.